Memphasys Ltd (AU:MEM) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Memphasys Ltd is on the brink of completing its clinical trial for the Felix™ System, having reached 90% completion with plans to finish by year’s end. The company is strategically shifting focus to obtain CE mark registration in Europe, aiming for a quicker market entry compared to the Australian approval process. This approach positions Memphasys to capitalize on larger market opportunities and potentially accelerate partnerships and investments.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
